Physician profile
Eric M Westerman
NPI 1538199849
$3,224.27
in general payments reported to CMS, 2019-2025
25 companies · $728 in 2025
The $728 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $500 · 2021: $131 · 2022: $126 · 2023: $274 · 2024: $453 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437 · Education: $17.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.33 |
| Education | $17.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,429.51 | 2019-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $480.53 | 2019-2025 | |
| Janssen Biotech, INC. | $245.58 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $165.79 | 2019-2022 | |
| Genentech USA, INC. | $159.91 | 2019-2025 | Gazyva |
| Horizon Therapeutics Plc | $116.10 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $107.07 | 2019-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $83.59 | 2023 | Idacio |
| Astrazeneca Pharmaceuticals LP | $61.07 | 2022-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $54.17 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $42.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.03 | 2020 | |
| Ani Pharmaceuticals, INC. | $25.94 | 2024 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $24.32 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $19.54 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.95 | 2025 | |
| Celltrion USA INC. | $17.89 | 2023 | Yuflyma |
| Pacira Therapeutics, INC. | $16.02 | 2019 | |
| Eisai INC. | $14.65 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.07 | 2019 | |
| Lilly USA, LLC | $13.71 | 2019 | |
| Merck Sharp & Dohme LLC | $13.43 | 2019 | |
| Sandoz INC. | $13.20 | 2023 | Hyrimoz |
| Antares Pharma, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Westerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.